MedTrace Logo

Post-COVID-19 Monitoring in Routine Health Insurance Data With Focus on Autoimmune Diseases (POINTED-AD)

NCT05606198 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 641407

Last updated 2023-09-11

No results posted yet for this study

Summary

The SARS-CoV-2 (Severe acute respiratory syndrome coronavirus type 2) infection was in 2020 responsible for new disease related chronic conditions which have been referred to as Post-COVID. To date it is still unknown how common this condition is and how it might effect the working of the Immune system. The aim of the study is therefore to monitor the onset of autoimmune diseases in a large observational study consisting of German health insurance data.

Conditions

  • Virus Diseases

Interventions

OTHER

Exposed to a SARS-CoV-2 infection

The study compared humans exposed to the SARS-CoV-2 infection with a matched group of those not exposed. No Intervention was applied.

Sponsors & Collaborators

  • InGef - Institut für angewandte Gesundheitsforschung Berlin GmbH

    collaborator UNKNOWN

  • BARMER Institut für Gesundheitssystemforschung (bifg)

    collaborator UNKNOWN

  • Techniker Krankenkasse

    collaborator OTHER

  • DAK Gesundheit

    collaborator OTHER

  • AOK PLUS

    collaborator INDUSTRY

  • IKK Classic

    collaborator UNKNOWN

  • Technische Universität Dresden

    lead OTHER

Principal Investigators

  • Jochen Schmitt, MD, MPH · Center for Evidence-Based Healthcare, Technische Universität Dresden

Eligibility

Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2022-05-01
Primary Completion
2023-01-25
Completion
2023-06-19

Countries

  • Germany

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05606198 on ClinicalTrials.gov